CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 74 enrolled
Drug / intervention
Daclatasvir +5 moredrug
Likely dose
Daclatasvir 3 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00874770
NCT00874770Phase 2Completed
CompareCT.gov

A Phase 2a Study of BMS-790052 in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype 1

Bristol-Myers Squibb·interventional·Posted Apr 3, 2009·Updated Oct 23, 2015

In Brief

A Phase 2 clinical trial evaluating Daclatasvir, Placebo, and 2 other interventions for Hepatitis C Infection. Completed, enrolled 74 participants across 14 sites in 2 countries.

Detailed Summary

The purpose of this study is to identify 1 or more doses of daclatasvir, which when used in combination with pegylated interferon alpha and ribavirin, are safe and demonstrate sufficient anti-hepatitis C virus activity.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C Infection
CountriesFrance, United States
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 3, 2009
Enrollment StartJun 1, 2009
Primary CompletionNov 1, 2009
Study CompletionJan 1, 2011
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 17.2 years ago

Interventions

Daclatasvirdrug

Tablets, oral, 3 mg, Daily, 48 weeks

Daclatasvirdrug

Tablets, oral, 10 mg, Daily, 48 weeks

Daclatasvirdrug

Tablets, oral, 60 mg, Daily, 48 weeks

Placebodrug

Tablet, oral, 0 mg, Daily 48 weeks

Peginterferon alpha-2adrug

Syringe, subcutaneous, 180 µg, Weekly, 48 weeks

ribavirindrug

Tablet, oral, 1000 or 1200 mg, based on weight, Daily, 48 weeks